OTCPK:VPTD.F

Stock Analysis Report

Executive Summary

Ventripoint Diagnostics Ltd., a medical device company, develops and commercializes diagnostic tools that monitor patients with heart disease primarily in Canada, the United States, and Europe.

Snowflake

Fundamentals

Weak fundamentals or lack of information.

Share Price & News

How has VentriPoint Diagnostics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-17.1%

VPTD.F

1.7%

US Medical Equipment

2.3%

US Market


1 Year Return

-47.8%

VPTD.F

10.1%

US Medical Equipment

5.6%

US Market

Return vs Industry: VPTD.F underperformed the US Medical Equipment industry which returned 10.1% over the past year.

Return vs Market: VPTD.F underperformed the US Market which returned 5.6% over the past year.


Shareholder returns

VPTD.FIndustryMarket
7 Day-17.1%1.7%2.3%
30 Day-21.9%-1.7%-1.0%
90 Day-43.0%-1.7%-0.7%
1 Year-47.8%-47.8%11.0%10.1%7.9%5.6%
3 Year-21.2%-21.2%70.4%65.2%45.6%36.3%
5 Year-88.1%-88.1%128.5%103.2%65.8%47.6%

Price Volatility Vs. Market

How volatile is VentriPoint Diagnostics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is VentriPoint Diagnostics undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether VentriPoint Diagnostics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as VentriPoint Diagnostics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of VPTD.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through VentriPoint Diagnostics regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is VentriPoint Diagnostics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

23.5%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as VentriPoint Diagnostics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of VPTD.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access VentriPoint Diagnostics's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has VentriPoint Diagnostics performed over the past 5 years?

-10.0%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: VPTD.F is unprofitable, and losses have increased over the past 5 years at a rate of -10% per year.

Accelerating Growth: Unable to compare VPTD.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VPTD.F is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).


Return on Equity

High ROE: VPTD.F's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets

ROA vs Industry: VPTD.F is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: VPTD.F is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is VentriPoint Diagnostics's financial position?


Financial Position Analysis

Short Term Liabilities: VPTD.F has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: VPTD.F has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: VPTD.F has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: VPTD.F's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: VPTD.F has a high level of physical assets or inventory.

Debt Coverage by Assets: VPTD.F has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: VPTD.F has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: VPTD.F has less than a year of cash runway if free cash flow continues to reduce at historical rates of -15.3% each year


Next Steps

Dividend

What is VentriPoint Diagnostics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate VPTD.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate VPTD.F's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if VPTD.F's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VPTD.F's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of VPTD.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of VentriPoint Diagnostics's salary, the management and board of directors tenure and is there insider trading?

1.4yrs

Average management tenure


CEO

George Adams (68yo)

9yrs

Tenure

CA$269,818

Compensation

Dr. George Adams, B.A.Sc., M.A.Sc., Ph.D., ICD.D., has been the Chief Executive Officer of VentriPoint Diagnostics Ltd. since October 1, 2010 and served as its President from October 1, 2010 to December 20 ...


CEO Compensation Analysis

Compensation vs. Market: George's total compensation ($USD204.57K) is about average for companies of similar size in the US market ($USD493.00K).

Compensation vs Earnings: George's compensation has been consistent with company performance over the past year.


Management Age and Tenure

1.4yrs

Average Tenure

Experienced Management: VPTD.F's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.


Board Age and Tenure

7.6yrs

Average Tenure

Experienced Board: VPTD.F's board of directors are considered experienced (7.6 years average tenure).


Insider Trading

Insider Buying: VPTD.F insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyCA$12,41404 Oct 19
Donald Segal
EntityIndividual
Shares110,000
Max PriceCA$0.11
BuyCA$12,41404 Oct 19
Alan Rabinowitz
EntityIndividual
Role
Member of the Board of Directors
Director
Shares110,000
Max PriceCA$0.11
BuyCA$7,52303 Oct 19
Ellen Briant
EntityIndividual
Role
Chief Financial Officer
CFO & Corporate Secretary
Shares66,666
Max PriceCA$0.11
BuyCA$190,76902 Oct 19
George Adams
EntityIndividual
Role
Chief Executive Officer
CEO & Director
Shares1,690,466
Max PriceCA$0.11
BuyCA$1,19316 Sep 19
George Adams
EntityIndividual
Role
Chief Executive Officer
CEO & Director
Shares15,000
Max PriceCA$0.08
SellCA$2,34620 Aug 19
George Adams
EntityIndividual
Role
Chief Executive Officer
CEO & Director
Shares22,275
Max PriceCA$0.11
SellCA$174,92721 Jan 19
George Adams
EntityIndividual
Role
Chief Executive Officer
CEO & Director
Shares1,500,000
Max PriceCA$0.12

Ownership Breakdown


Management Team

  • George Adams (68yo)

    CEO & Director

    • Tenure: 9yrs
    • Compensation: CA$269.82k
  • Justin Leushner

    President

    • Tenure: 0.08yrs
  • Ellen Briant

    CFO & Corporate Secretary

    • Tenure: 6.7yrs
    • Compensation: CA$125.74k
  • Desmond Hirson

    Chief Technology Officer

    • Tenure: 0.08yrs
    • Compensation: CA$317.92k
  • Alvira Macanovic

    Senior Director of Operations

    • Tenure: 1.8yrs
  • Jim Graba

    Application Specialist & Chief Trainer

    • Tenure: 1.4yrs
  • Jessica Naman

    Director of Marketing

    • Tenure: 1yrs

Board Members

  • David Willis

    Director

    • Tenure: 3.9yrs
    • Compensation: CA$48.09k
  • Sam Schwartz

    Chair of Business Advisory Committee

    • Tenure: 1.6yrs
  • Danny Dalla-Longa (65yo)

    Director

    • Tenure: 14.4yrs
    • Compensation: CA$40.77k
  • George Adams (68yo)

    CEO & Director

    • Tenure: 9yrs
    • Compensation: CA$269.82k
  • Scott Solomon

    Member of Scientific Advisory Board

    • Tenure: 7.6yrs
  • David Sahn

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Mark Lewin

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Michael Gatzoulis

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Richard Krasuski

    Member of Scientific Advisory Board

    • Tenure: 8.4yrs
  • Alan Rabinowitz

    Director

    • Tenure: 3.8yrs
    • Compensation: CA$40.77k

Company Information

VentriPoint Diagnostics Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: VentriPoint Diagnostics Ltd.
  • Ticker: VPTD.F
  • Exchange: OTCPK
  • Founded:
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: CA$6.529m
  • Listing Market Cap: CA$4.950m
  • Shares outstanding: 68.73m
  • Website: https://www.ventripoint.com

Location

  • VentriPoint Diagnostics Ltd.
  • 2 Sheppard Avenue East
  • Suite 605
  • Toronto
  • Ontario
  • M2N 5Y7
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
VPTTSXV (TSX Venture Exchange)YesCommon SharesCACADSep 2007
VPTD.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDSep 2007
5V7DB (Deutsche Boerse AG)YesCommon SharesDEEURSep 2007

Biography

Ventripoint Diagnostics Ltd., a medical device company, develops and commercializes diagnostic tools that monitor patients with heart disease primarily in Canada, the United States, and Europe. The company ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/17 00:11
End of Day Share Price2019/10/16 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.